Annals of Neurodegenerative Disorders

Nutraceutical Therapy for Patients Suffering from Myalgic Encephalomyelitis or Chronic Fatigue Syndrome (ME or CFS), Post-Covid Syndrome (PCoS), or Alzheimer Disease (AD)

Short Communication | Open Access | Volume 6 | Issue 1

  • 1. Consulting Specialist for Internal Medicine, Endocrinology and Metabolic Diseases, Fertility-Belgium Clinic, Belgium
  • 2. Specialist Internal Medicine and Ultrasonography, Belgium
+ Show More - Show Less
Corresponding Authors
Frank Comhaire, Consulting Specialist for Internal Medicine, Endocrinology and Metabolic Diseases, Fertility-Belgium Clinic, Weststraat, 16, 9880 Aalter, Belgium, Tel: 32 475618555; Email: frank.comhaire@telenet.be

In the present observational prospective open-label study the effect was evaluated of treating 113 patients suffering from myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) or from post-COVID syndrome (PCoS, also called long-COVID) with either the nutraceutical QALY® plus sodiumdichloroacetate and meldonium, or with infusions containing magnesium-sulphate plus multivitamins, or with glutathione plus stem cells. Overall 86% of patients reported a variable degree of decreased fatigue after 4 to 6 weeks, with no significant difference between the two modes of treatment. In addition, in 2 patients with evolutive age-related Alzheimer’s disease (AD) receiving oral therapy together with the extract of Hericium echinaceus, mental deterioration could be halted for 48 and 72 months respectively.

Taking into account the limitations of the present preliminary study it is suggested that complementary treatment may be considered as add-on to conventional therapy in ME/CFS or PCoS patients, as well as in patients suffering from age-related AD.


Myalgic encephalomyelitis, Chronic fatigue syndrome, post-COVID syndrome, Long-COVID, Nutraceutical treatment, infusion therapy, Alzheimer’s disease, stem cell therapy


Comhaire F, Pen J, Deslypere JP (2022) Nutraceutical Therapy for Patients Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Post-Covid Syndrome (PCoS), or Alzheimer Disease (AD). Ann Neurodegener Dis 6(1): 1032.


Myalgic encephalomyelitis/chronic fatigue syndrome (ME/ CVS) and post (acute)-COVID syndrome (PCoS), also called longCOVID, present many similar clinical manifestations. External factors may induce these chronic diseases in persons with certain genetic or acquired characteristics, like a great sense of responsibility. Infection, either bacterial or viral [1], physical or emotional trauma, surgery, or long-term stress may induce systemic immune disorder [2,3]. With activation of inflammatory mechanisms, including elevated cytokine levels. These may persist due to epigenetic hypermethylation of genes involved with inflammation [4]. Evidence suggests that inflammation and oxidative overload can impair mitochondrial aerobic metabolism by increased phosphorylation of pyruvate dehydrogenase, resulting in lowered generation of adenosine triphosphate (ATP), and shifting glucose-pyruvate to anaerobic metabolism through the Cori cycle with excessive production of lactate [1]. This may explain post-exertion fatigue and poor recovery, as well as cerebral complaints such as brain fog, cognitive impairment, memory malfunction, and sleep disturbance. The regular intake of sodium-dichloroacetate (DCA-laboratory, Vilnius, Lithuania) and of meldonium (Mildronate®, Grindex, Riga, Latvia), counteracting these metabolic alterations, were found to be effective in treating many patients with ME/CFS [5].

Mechanisms activating neurodegenerative diseases and early development of dementia were found to be stimulated postCOVID [6]. However, cardio-vascular disease like atherosclerosis, and metabolic diseases such as insulin resistance and diabetes, as well as unhealthy life style equally increase the risk of Parkinson’s and Alzheimer’s diseases (AD), probably also because of inflammatory and oxidative overload [7]. In contrast, high flavonoid intake is associated with significantly reduced risk of AD [8,9].

Based on these considerations we have given particular natural substances to patients with the diseases mentioned above, either orally or in intravenous infusions, and we have registered their reaction in terms of improving fatigue and general well-being.


All 113 patients had been diagnosed to suffer from ME/CFS or PCoS either by university reference centres for these diseases or after clinical investigation by one of the authors.

Oral treatment consisted of the combination of the nutraceutical QALY® (Jona Pharma, Elversele, Belgium; ingredients in appendix) with a formulation containing sodiumdichloroacetate (CDA-lab, Vilnius, Lihuania; ingredients in appendix) and meldonium (Mildronate®, Grindex, Riga, Latvia). This was given to 85 patients.

Of the 28 patients treated by infusion therapy 20 received 2 or 3 gr of Magnesium-sulphate together with multivitamins (SoluVit®, Sterop, Brussels, Belgium). Eight patients were given Magnesium-sulphate together with a mixture of glutathione and stem cells (Completté®, Kuhra Vitae Derma Pharma, Lucerne, Switzerland; ingredients in appendix).

Before initiation of treatment 105 patients completed the Fatigue Severity Score (FSS) [10] and this was repeated at the end of treatment after 4 to 6 weeks.

All data were collected in the spreadsheet of the MedCalc statistical program [11], and parametric statistical tests were applied as required.

Two patients with progressive deterioration of Alzheimer disease (AD) were given oral therapy together with the extract Hericium echinaceus. In addition, insulin resistance was treated with the extract of Momordica charantia in one of them, and methylprednisolone IV was given intermittently in the other case presenting immune disorder with elevated IgA [12]. The evolution of the disease, as recorded by their care takers, was followed-up during 72 and 48 months respectively.


There was no statistical difference in the epidemiologic characteristics between patients included in the different treatment groups, nor between the cases with ME/CFS or PCoS. Only the duration of the disease was much longer in the patients belonging to the first group (mean 9.4 yrs; SD: 5.4 yrs) as compared to that of patients in the second group (mean 10.3 mths, SD: 4.7 mths). Overall 83 % were female and the mean age was 43.9 yrs (SD11.4 yrs). Of the 113 patients, 86 % reported improvement, defined as FSS after treatment being lower than that before treatment. The FSS decreased with an average of 23 % among the successful cases. The success rate among the patients treated by infusion therapy (89.3%) was similar to that of oral treatment (84.7%).

None of the patients reported adverse effects and all cases on oral therapy continued treatment. Five out of the 28 cases on infusion therapy abandoned treatment because of the relatively high cost, or because of technical problems at venepuncture. In one of the latter cases the Competté® was alternatively given by slow intramuscular injection, on the explicit request of the patient who experienced major therapeutic benefit.

Among the patients with AD no significant improvement of the mental state was recorded, but the diseases could be stabilized and progression of dementia could be halted during respectively 72 and 48 months of follow-up so far.


Signs and symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are similar to those seen in many patients with so-called Long-COVID or Post (acute)-COVID Syndrome (PCoS). Both conditions are probably related to persistent inflammation and immune deregulation, both at the somatic and at the cerebral level. In addition, patients who suffered severe COVID have been found to run a greater risk of developing neurodegenerative diseases, Alzheimer disease (AD) in particular [6].

Conventional treatment of these diseases has focussed on promoting physical recovery, memory training and adaptation of the working and living environment. Though certainly indicated and helpful [13], the effectiveness of this approach is moderate, leaving the need for complementary therapy.

Recently we have published the results of pragmatic, real life studies of nutraceutical treatment using the combination of vitamins, mineral salts and plant extracts with antioxidant, antiinflammatory and adaptogen capacity. There is evidence that this nutraceutical does reduce epigenetic hypermethylation [14], which has been shown to play an important role in COVID-19 infection [4]. The nutraceutical was combined with substances optimizing mitochondrial metabolic function. As an alternative to, or in combination with the oral treatment, intravenous infusion therapy was given using magnesium-sulphate, multivitamins, essential amino acids [15], and – more recently – stem cells.

The present paper summarizes the preliminary results of these therapeutic approaches based on observational, open-label prospective registration in a total of 113 cases in two different outpatient clinics. Overall 86% of patients reported a variable degree of reduced fatigue and improvement of general wellbeing within 4 to 6 weeks of treatment.

Since several biological mechanisms leading to AD may be activated by COVID infection, and since chronic inflammation and oxidative overload are also involved in the development of age-related AD, oral therapy was given to 2 patients with evolutive AD. Treatment could not improve their condition, but it prevented further deterioration.

The present finding should be interpreted with great caution because the number of observations is small and there is no comparison with a control group. However, the preliminary results should justify the initiation of a randomized placebocontrolled double-blind trial, using either oral or infusion therapy as add-on in patient who respond poorly to conventional treatment.

The results of pragmatic real-life study suggest a significant, though variable degree of improvement of fatigue and of general well-being and quality of life can be obtained in the majority of patients. Most of the patients wished to continue their therapy, since improvement seemed to be maintained or even continued to increase in the majority of them.


Ingredients of QALY®: Astaxanthin (biomass of Haematococcus pluvialis); Oxido-reductase Ubiquinol Q10; Pine bark extract (Pinus maritima); Extract of roseroot (Rhodiola rosea); Vitamin B9 (folic acid); Vitamin B12 (methylcobalamine), Selenomethionine; Zinc- bisglycinate; Krill oil.

Ingredients of DCA formula: Sodium-dichloroacetate; Vitamin B1 (Thiamine); Alpha lipoic acid; Ubiquinol Q10.

Ingredients of Completté®: Bio-glutathione; Hesperidin; Ascorbic acid; Hyaluronic acid; m-tranexamic acid; Argan stem-cell, Bio-stem cell.


The first author owns the Belgian patent of some of the ingredients of QALY®. The study did not benefit from any financial support.


The authors express their gratitude to the staff members of the Fertility-Belgium clinic and of the Senses praktijkhuis for their technical assistance in executing the infusion therapies.


1. Comhaire F. Treating patients suffering from myalgic encephalopathy/ chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof–of-principle pilot trial. Med Hypotheses. 2018a; 114: 45-48.

2. Comhaire F, Devriendt G. Chronic fatigue syndrome (CFS) or “systemic immune disorder” (SID)?. Internal Medicine: Open Access. 2016; 6: 5.

3. Comhaire F, Deslypere JP. News and views in myalgic encephalopathy /chronic fatigue syndrome (ME/CFS): the role of co-morbidity and novel treatments. Medical Hypotheses 2020; 134: 109444.

4. Chlamydas S, Papavassilou AG, Pioen C. Epigenetic mechanisms regulating COVID-19 infection. Epigenetics. 2021; 16: 263-270.

5. Comhaire F. Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not? Medical Hypotheses. 2018; 120: 65-67.

6. Reiken S, Sirrefeld L, Dridi H, Yang Liu, Xiaoping Liu, Andrew R Marks. Alzheimer’s-Like signalling in brains of COVID-19 patients. Alzheimers Dement. 2022; 18: 955-965.

7. Armstrong AA. Risk factors for Alzheimer’s disease. Folia Neuropathol. 2019; 57: 87-105.

8. Commenges D, Scotet V, Renaud S, H Jacqmin-Gadda, P BarbergerGateau, JF Dartigues, et al. Intake of flavonoids and risk of dementia. Eur J Epidemiol. 2000; 16: 357-363.

9. Gildawie KR, Galli RL, Shukitt-Hale B, Carey AN. Protective effects of foods containing flavonoids on age-related cognitive decline. Curr Nutr Rep. 2018; 7: 39-48.

10. Krupp LB, LaRocca NG, Muir-Nash J, AD Steinberg. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46: 1121–3.

11. Schoonjans F, Zalata A, Depuydt CE, Comhaire T. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed. 1996; 48: 257-262.

12. Comhaire F. Novel perspectives for treating and preventing dementia by complementary medicine. Clinical Studies & Medical Case Reports. 2020. 1-6.

13. Halabchi F, Selk-Chaffari M, Tazesh B, Mahdavian B. The effect of exercise rehabilitation on COVID-19 outcomes: a systematic review of observational and intervention studies. Sport Sci Health. 2022; 28: 1-19.

14. Comhaire F, Decleer W. Can the biological mechanisms of ageing be corrected by food supplementation. The concept of health care over sick care. Aging Male. 2020 Jan 24:1-12.

15. Comhaire F, Deslypere JP, Pen J. Pragmatic clinical comparison of two modes of treatment in patients with ME/CFS or Post-Covid syndrome. SM Journal of Neurology and Neuroscience. 2022; 8: 1-4.

Comhaire F, Pen J, Deslypere JP (2022) Nutraceutical Therapy for Patients Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Post-Covid Syndrome (PCoS), or Alzheimer Disease (AD). Ann Neurodegener Dis 6(1): 1032.

Received : 18 Jul 2022
Accepted : 23 Aug 2022
Published : 25 Aug 2022
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X